UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | May 1, 2006 |
Emisphere Technologies, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| Delaware | 1-10615 | 13-3306985 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 765 Old Saw Mill River Road, Tarrytown, New York | | 10591 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | 914-347-2220 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On May 1, 2006 Emisphere Technologies, Inc.("Emisphere") announced that Novartis Pharma AG ("Novartis") has notified Emisphere that Novartis will initiate the development of an oral human growth hormone (rhGH) product using Emisphere's eligen® delivery technology. Pursuant to the terms of a license agreement executed by Emisphere and Novartis on September 23, 2004, Emisphere is entitled to a $5 million development commencement milestone payment as a result of the Novartis decision to proceed with product development. Novartis notified Emisphere that it had initiated a multidose study in growth hormone-deficient adults with the oral formulation of rhGH in Q1 this year. Once finished, the results of the trial will be communicated in an appropriate and timely manner.
Emisphere is entitled to receive additional milestones and royalties from Novartis should an oral growth hormone product be commercialized using Emisphere's eligen® technology.
Item 9.01 Financial Statements and Exhibits.
Exhibits
(c)
Exhibit 99.1 - Press Release of Emisphere Technologies, Inc. dated May 1, 2006.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | Emisphere Technologies, Inc. |
| | | | | |
| May 3, 2006 | | By: | | Elliot Maza
|
| | | | |
|
| | | | | Name: Elliot Maza |
| | | | | Title: Chief Financial Officer |
Exhibit Index
| | | |
| Exhibit No. | | Description |
| |
|
99.1 | | Press Release of Emisphere Technologies, Inc. dated May 1, 2006. |
